Trop-2 as an Actionable Biomarker in Breast Cancer.
作者信息
Cursano Giulia, Frigo Emanuele, Sajjadi Elham, Ivanova Mariia, Venetis Konstantinos, Guerini-Rocco Elena, Criscitiello Carmen, Curigliano Giuseppe, Fusco Nicola
机构信息
Division of Pathology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
School of Pathology, University of Milan, Milan, Italy.
出版信息
Curr Genomics. 2023 Nov 22;24(3):129-131. doi: 10.2174/1389202924666230726112233.
Abstract
摘要
相似文献
1
Trop-2 as an Actionable Biomarker in Breast Cancer.
Curr Genomics. 2023 Nov 22;24(3):129-131. doi: 10.2174/1389202924666230726112233.
2
An electrochemical biosensor to assay Trop-2 of breast cancer cells fabricated by methylene blue-assisted assembly of DNA nanoparticles.
Biosens Bioelectron. 2024 Feb 15;246:115907. doi: 10.1016/j.bios.2023.115907. Epub 2023 Dec 5.
3
Trop-2 as a Therapeutic Target in Breast Cancer.
Cancers (Basel). 2022 Nov 30;14(23):5936. doi: 10.3390/cancers14235936.
4
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.
Breast Cancer Res Treat. 2024 Jun;205(3):589-598. doi: 10.1007/s10549-024-07292-z. Epub 2024 Mar 8.
5
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Ann Oncol. 2021 Sep;32(9):1148-1156. doi: 10.1016/j.annonc.2021.06.002. Epub 2021 Jun 8.
6
Trop-2 is a determinant of breast cancer survival.
PLoS One. 2014 May 13;9(5):e96993. doi: 10.1371/journal.pone.0096993. eCollection 2014.
7
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
Breast. 2022 Dec;66:169-177. doi: 10.1016/j.breast.2022.10.007. Epub 2022 Oct 18.
8
Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer.
Oncotarget. 2020 Oct 27;11(43):3849-3862. doi: 10.18632/oncotarget.27766.
9
Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance.
Breast Cancer. 2022 Nov;29(6):1076-1087. doi: 10.1007/s12282-022-01389-3. Epub 2022 Jul 27.
10
Immunity to Trop-1, a newly identified breast cancer antigen, inhibits the growth of breast cancer in mice.
Vaccine. 2010 Nov 16;28(49):7757-63. doi: 10.1016/j.vaccine.2010.09.057. Epub 2010 Sep 29.
本文引用的文献
1
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
J Clin Oncol. 2024 Jul 1;42(19):2281-2294. doi: 10.1200/JCO.23.01909. Epub 2024 Apr 23.
2
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trial.
Ann Oncol. 2024 Mar;35(3):293-301. doi: 10.1016/j.annonc.2023.11.018. Epub 2023 Dec 12.
3
Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings.
Cancers (Basel). 2023 Mar 13;15(6):1744. doi: 10.3390/cancers15061744.
4
Correlation of TROP-2 expression with clinical-pathological characteristics and outcome in triple-negative breast cancer.
Sci Rep. 2022 Dec 28;12(1):22498. doi: 10.1038/s41598-022-27093-y.
5
Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer.
BMC Cancer. 2022 Sep 24;22(1):1014. doi: 10.1186/s12885-022-10076-7.
6
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis.
NPJ Breast Cancer. 2022 Jun 9;8(1):72. doi: 10.1038/s41523-022-00439-5.
7
TROP2: a potential marker in diagnosis of thyroid neoplasms.
Ir J Med Sci. 2023 Feb;192(1):99-103. doi: 10.1007/s11845-022-02976-1. Epub 2022 Mar 30.
8
Oncogene-mediated metabolic gene signature predicts breast cancer outcome.
NPJ Breast Cancer. 2021 Oct 28;7(1):141. doi: 10.1038/s41523-021-00341-6.
9
Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers.
Bosn J Basic Med Sci. 2022 Feb 1;22(1):14-21. doi: 10.17305/bjbms.2021.6100.
10
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Ann Oncol. 2021 Sep;32(9):1148-1156. doi: 10.1016/j.annonc.2021.06.002. Epub 2021 Jun 8.
Zotero 插件